Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115146) titled 'Clinical and Mechanism Study on Jianpi-Yishen-Qinghua-Heluo Decoction in the Treatment of Diabetes Kidney Disease' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Condition:
Diabetes Kidney Disease
Intervention:
Control Group:Basic treatment plus empagliflozin (Manufacturer: Boehringer Ingelheim Pharma GmbH & CO.KG
Approval Number: National Medical Product Administration Approval No. HJ20201008), specification: 10 mg per tablet, administered orally, 1 tablet once daily.
Treatment G...